TY  - JOUR
T1  - INcentives for new antibiotics
AU  - Mitka M
Y1  - 2012/08/08
N1  - 10.1001/jama.2012.9558
JO  - JAMA
SP  - 558
EP  - 558
VL  - 308
IS  - 6
N2  - 
The legislation (S 3187; http://tinyurl.com/7kz57hk) primarily requires drug and device manufacturers to pay user fees to fund the FDA's approval process for drugs and medical devices. But some of the fees are earmarked to bolster the agency's safety oversight and to pay for other programs, such as creating incentives for antibiotic development.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.9558
UR  - http://dx.doi.org/10.1001/jama.2012.9558
ER  -